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All patients with metastatic non-small cell lung cancer (NSCLC) should undergo EGFR 
mutation testing and receive appropriate therapy, however, variation in testing and 
therapy use is a growing concern. The objective of this investigation was to identify 
physicians’ practice patterns and predictors of physicians’ genetic testing and targeted 
therapy use in metastatic lung cancer. 
Methods 
Approximately 360 physicians caring for CanCORS patients with lung or colorectal 
cancer completed a survey between 2012 to 2013 assessing attitudes and practices with 
respect to genetic testing and targeted therapies. The outcome variables were: (1) 
physicians’ reports that they would likely recommend (a) EGFR testing and (b) ERCC1 
testing for a hypothetical patient; (2) physicians’ reports that they would choose 
Erlotinib as first-line regimen if a patient was found to have an EGFR mutation.  
Results 
Physicians who often obtained information from peer-reviewed medical literature 
reported that they would recommend EGFR testing more than those who rarely/never 
used this source (p=0.068).  Physicians who were younger, had fewer years since 
graduation from medical school, graduated from a U.S./Canadian school, and were 
Asian or White chose Erlotinib more than physicians without these features (p=0.008, 
p=0.011, p=0.068, and p=0.021). Physicians who reported local/national guidelines as 
having a high impact on their test use, and those who reported obtaining information 
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often from local colleagues, national/international experts, or national guidelines, chose 
Erlotinib more than their counterparts (p=0.066, p=0.062, p=0.037, and p=0.041). 
Those with solo practice types were the least likely to recommend Erlotinib compared to 
other practice types (p=0.013). After adjustment, gender, age, race, practice type, 
impact of national guidelines, and obtaining information from national/international 
experts all remained significantly associated with choice of Erlotinib (OR[CI]=2.07 
[1.12, 3.81] and OR[CI]=1.56 [0.96, 2.52], respectfully). 
Conclusion 
It can be inferred that the variation seen in testing and treatment in patients with NSCLC 
is largely due to the differences in physicians’ knowledge, which are the result of diverse 
sources of information. The implications that follow the findings of the present paper 
include: the importance of considering the content and format of reports and guidelines 
directed towards clinicians; and the need for easily accessible interfaces that provide the 

















Background of NSCLC 
 
Lung cancer accounts for 13% of all new cancer cases.1 About two out of three people 
diagnosed with lung cancer are 65 or older, and fewer than 2% of all cases are found in 
people younger than 45. The average age at the time of diagnosis is about 70 years old.2  
 
There are two types of lung cancer: Non-small cell lung cancer (NSCLC) which accounts 
for about 85-90% of lung cancers, and Small cell lung cancer (SCLC) which accounts for 
about 10-15% of lung cancers. Fifty-four percent of NSCLC patients are male and 46% 
are female.1 Eighty-three percent of NSCLC patients are Caucasian, 10% are African 
American, 6% are Asian Pacific Islander, and 2.5% are Asian Pacific Islander female.3 
 
The Role of EGFR in NSCLC 
 
Epidermal growth factor receptor (EGFR) is a member of the ErbB family of cell surface 
tyrosine kinases4 and is encoded on chromosome 7.5 The receptor belongs to the 
HER/ErbB family of tyrosine kinases.17 The function of the receptor is to regulate both 
cell proliferation and apoptosis via signal transduction pathways.6 In a healthy cell, EGFR 
permits the cell to grow and divide. When there are too many receptors caused by a 
mutation, as is the case with cancer, the cancer cells continue to grow and divide.7  
 
Approximately 60% of NSCLCs express EGFR and EGFR mutations occur in 
approximately 10-15% of tumors, which represents about 14,000 to 20,000 patients. 
Approximately 90% of these mutations are exon 19 deletions or exon 21 L858R point 
mutations.8 These mutations increase the kinase activity of EGFR, leading to 
hyperactivation of downstream pro-survival signaling pathways.9  
 
Given that more than 60% of NSCLCs express EGFR and 10-15% of these harbor 
mutations, EGFR has become an important therapeutic target for the treatment of these 
tumors.10 Research studies have shown that EGFR mutations can predict whether certain 
types of drugs, called tyrosine kinase inhibitors (TKIs), can help treat lung cancer. In 
phase III randomized trials involving patients with advanced NSCLC and targeted 
therapy, EGFR mutation-positive (M+) status has been shown to be predictive of 
significant benefit from EGFR TKIs.11,12,13 Findings from key clinical trials comparing 
EGFR TKI therapy with chemotherapy show a clinical benefit with EGFR TKI treatment – 
specifically in patients with EGFR M+ NSCLC.12,13,14,15,16,17,18 
 
ERCC1 Expression in Lung Cancer 
 
The excision repair cross-complementation group 1 (ERCC1) protein plays a role in 
repairing DNA damage.19 Prior studies have shown that high tumor levels of ERCC1 
predict a benefit of adjuvant chemotherapy in patients with NSCLC, however, the value 
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of testing has been questioned. Although the role of ERCC1 in DNA repair is important, 
ERCC1 expression, measured using commercially available antibodies, is not currently 





EGFR mutation testing is recommended in patients with non-squamous NSCLC (i.e., 
adenocarcinoma, large cell carcinoma) or in NSCLC not otherwise specified (NOS).20 
Results of the test should guide treatment decisions to ensure patients receive treatment 
according to cancer type and mutation subtype.21 Patients with NSCLC who test positive 
for an EGFR exon 19 deletion or exon 21 substitution mutation generally respond 
positively to treatment with an EGFR TKI (Erlotinib).  
 
ERCC1 testing has not been recommended in national guidelines.22 
 
Statement of problem 
 
EGFR testing is a critical component when making treatment decisions in advanced 
NSCLC, as it helps match each patient with the most appropriate therapy as early as 
possible.23 EGFR M+ patients are more likely to respond to EGFR TKIs, and so it is 
important to identify the biomarker status of all patients with advanced NSCLC.11 On the 
other hand, ERCC1 testing has questionable utility in advanced NSCLC and has not been 
recommended in national guidelines. While genetic testing has been used to profile 
NSCLC with continued success, variation in genetic testing and targeted therapy use are 
a growing concern. A study done in 1996-1997 with 350 physicians from five difference 
clinical scenarios showed variability in treatment recommendations and perceived 
treatment efficacy both within and between specialties.24 More recently, an international 
survey assessing EGFR mutation testing rates and treatment practices in lung cancer 
showed that almost a quarter of newly diagnosed NSCLC patients in the United States 
were not tested for EGFR mutation.21 The main reasons for not testing patients, 
according to the surveyed oncologists, included: histology (tissue and cell type of 
tumor), insufficient tissue to perform the test, poor general health of the patient, and 
long turnaround time of the results.21 According to the same survey, one in four patients 
in the United States treated by surveyed oncologists were started on first-line treatment 
before test results were received and 60% of oncologists do not determine their 
treatment decisions based on a patient’s EGFR mutation subtype.21 Furthermore, 
physicians’ knowledge of and compliance with practice guidelines are generally low, 
which may result in too few recommendations for testing and subsequently improper 
treatment recommendations for therapy.25 Another study on the beliefs of 
pulmonologists and thoracic surgeons in the therapeutic approach to NSCLC confirmed 
that some physician beliefs regarding treatment efficacy in NSCLC care did not reflect 
the results of randomized, controlled trials studying these therapies, underscoring how 
physician attitude toward the disease and available therapies may color treatment 
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recommendations.26 This raises important questions about variable expertise of 
physicians, adherence to guidelines, and ultimately, the reliability of the physicians’ 
guidance that crucially underpins the management and treatment of NSCLC.27  
 
Objective(s) of Investigation  
 
Because of the aggressive and incurable nature of metastatic NSCLC, selection of first-
line therapy is a critical decision point in the treatment of advanced lung cancer. The 
objective of the investigation (thesis) is to identify practice patterns and predictors of 
genetic testing and targeted therapy use in metastatic lung cancer. The thesis will 
provide insight into reasons for variability in testing and therapy choice in order to 
identify areas of improvement to ultimately ensure that future patients will receive 




Study Design & Participants 
 
The CanCORS study was an observational study designed to evaluate cancer care and 
outcomes among patients with lung or colorectal cancer newly diagnosed from 2003 to 
2005 and living in one of five geographic regions (northern California, Los Angeles, 
Alabama, Iowa, or North Carolina) or receiving care in one of five health maintenance 
organizations or one of 15 Veterans Affairs (VA) sites.28,29 The characteristics of patients 
enrolled in CanCORS have been shown to be representative of patients identified by the 
Surveillance, Epidemiology, and End Results (SEER) Program for both lung and 
colorectal cancer.30 Physicians caring for CanCORS patients were identified from a 
baseline patient survey, a follow-up survey 1 year after diagnosis, a follow-up survey in 
2012, and medical records. The follow-up survey of CanCORS physicians was only 
performed from the summer of 2012 to the fall of 2013, and was the data used for this 
study’s analysis.29  
 
The study was conducted in two waves: the patient cohort was initially enrolled during 
the first wave (CanCORS I), and yielded 2,013 eligible participants with lung cancer and 
4,223 with colorectal cancer who completed one of the baseline patient surveys. In the 
second wave (CanCORS II) additional data were collected on a subset of the patients and 
a physician survey was conducted with medical oncologists who were identified for the 
CanCORS I physician survey plus any new medical oncologists identified during the 
interviewers with members of the CanCORS II cohort. Approximately 900 physicians 
were asked to complete the survey by mail/web to assess attitudes and practices with 
respect to cancer survivor care and new, targeted cancer therapies. Of these 900, around 






To understand how physicians’ beliefs and characteristics influence the processes of care 
and outcomes of patients in the CanCORS study, physicians who made referrals for 
cancer care, treated cancer-related symptoms, or were involved in decisions about 
treatment were surveyed. The survey consisted of three primary domains: (1) physicians 
use and understanding of biomarkers and new biologic agents, (2) physician beliefs and 
practice re: cancer surveillance, and (3) physician practice characteristics and financial 
arrangements and demographics. The survey included two experiments in which 
vignettes (Appendix, questionnaire question 10 and 15) were modified in the three 
different versions of the survey. Respondents were randomly assigned one of these three 
versions. The experiment and subsequent vignette focused on in this study asks about 
EGFR testing for lung cancer and varies by race/ethnicity of the patient in the question 
(white vs. Asian vs. black). Enrollment began in July 2012 and ended October 2013.31  
 
Physician Survey Content Used and Rationale for Use31 
Domain Content Rationale 
Physician demographic 
characteristics 
Age, sex, race and ethnicity, 
year graduated from medical 
school, U.S./Canadian medical 
graduate  
Potential predictors of care 
delivered to patients 
Physician practice 
characteristics 
Practice type, size, and 
ownership, and factors that 
influence income 
Potential predictors of care 
delivered to patients  
Volume of lung patients Number of new lung cancer 
patients seen in a typical 
month 
Potential predictor of cancer care 
delivery 
Beliefs and utilization of 
biologic therapies recently 
approved by the FDA 
Use of biologic therapies, 
understanding of 
recommendations and the 
supporting evidence, 
knowledge of potential 
benefits and toxicity for 
patients, and use of these 
drugs in certain clinical 
scenarios 
Understand how physicians are 
using biologic therapies and if 
they are using them appropriately 
Beliefs about the role of 
molecular biomarkers in the 
care of patients with lung 
cancer 
Understanding and utilization 
of molecular 
profiling/genomic testing 
(EGFR mutations, clinical 
phenotypes, etc.) 
Personalization of treatment 
recommendations 
Understand whether physicians 
are appropriately recommending 
molecular profiling of patients 





(1)   Physicians’ reports that they would likely recommend the following tests for 
the hypothetical patient (Appendix, questionnaire question 15): 
a.   EGFR 
b.   ERCC1 
(2)   Physicians’ reports that they would choose Erlotinib as first-line regimen if a 
patient was found to have an EGFR mutation (Appendix, questionnaire 
question 16) 
 
Statistical Analysis  
 
Multiple imputation was used to adjust for missing item responses when analyzing the 
provider survey data. Frequency distributions were examined to develop groupings for 
responses to some survey items to facilitate their comparison and interpretation. For 
physician race/ethnicity, two race/ethnicity questions (Appendix, questionnaire question 
36 and 37) were used to create four race categories: Non-Hispanic White, Asian, Other, 
and Unknown. Age was calculated by subtracting the physicians’ reported birth year 
from the date the survey was taken. Specialty was grouped into 5 categories: oncology, 
hematology, oncology/hematology, specialized oncology/hematology (other, not lung), 
and lung hematology/oncology. For the first outcome variable on EGFR and ERCC1 
testing (Appendix, questionnaire question 15), ‘Very likely’ and ‘Somewhat likely’ were 
combined and ‘Very unlikely’ and ‘Somewhat unlikely’ were combined. Aside from 
comparing the association between the hypothetical patients’ race (Asian for survey A, 
black for survey B, and white for survey C) and EGFR or ERCC1 testing, the survey 
responses were combined across all three types. The second outcome variable was 
dichotomized with Erlotinib equal to 1 and all other treatment choices equal to 0.  
 
Chi-square or Fisher’s exact tests were used to determine physician demographic, 
practice characteristics, and beliefs associated with outcome variables (1) and (2), where 
appropriate. Means were compared used t-test and ANOVA, where appropriate. Variables 
that were significant at the 0.10 level in the bivariate analysis were included in a 
multivariable logistic regression model to determine the independent association of each 
variable with chosen outcomes. Because the study was more descriptive in nature, an 
alpha level of 0.10 was considered significant to allow for further analysis and discussion 
of potentially important variables.  
 
All statistical analyses were performed using SAS University Edition (SAS Institute Inc., 











Description of the physician demographic characteristics can be found in Table 1. Among 
the 357 physicians who completed the survey, 75% were male and 25% were female. 
Median age was 54 years old, with the youngest physician being 36 and oldest being 82 
years old. The majority of the sample identified as non-Hispanic White or Asian (66% 
and 23%, respectfully), while the remaining 9% of physicians identified as either non-
Hispanic Black, Native Hawaiian, other race, or multiracial, and 2% said their 
race/ethnicity was unknown. More than half of physicians said that Oncology was their 
primary specialty and almost a third said that Hematology/Oncology was their primary 
specialty, while only 1% said that their primary specialty was Thoracic (Lung) 
Hematology/Oncology. The sample was evenly split between those that were involved 
with teaching medical students/residents and those that were not involved. A little more 
than three quarters of the sample graduated from a U.S./Canadian medical school, and 




Description of the physician practice characteristics can be found in Table 2. The 
majority of physicians in the sample described their primary practice as a single specialty 
group and multi-specialty group (39% and 41%, respectfully), and one or more 
physicians, or a physician-owned corporation, was the most frequently reported owner of 
the practice (44%). The median reported percentage of the practice that included 
patients with lung cancer was 19%, with a range of 0-100%. Most physicians reported 
being paid by salary for their clinical work in 2011 (69%). Of those who were not paid 
by salary, exclusively fee-for-service and predominately fee-for-service best described 
personal income (46% and 37%, respectfully). When asked how, if at all, income is most 
likely to change as a result of prescribing/administering more chemotherapy and of 
ordering more genetic testing, most physicians said that income was not likely to change 
(70% and 88%, respectfully).  
 
Preferences & Beliefs 
 
Overall, the test predicting clinical benefit from specific treatments was reported to have 
the highest impact on the decision to request somatic genetic testing among the study 
sample (Table 3). Around 94% of physicians said that whether or not local or national 
guidelines have been issued on test use had a moderate or high impact on their decision 
to request genetic testing. On the other hand, FDA alerts about availability of testing or 
patient requests/inquires about the test was most commonly chosen as having a low 
impact on the decision to test among the sample.  
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Approximately three-quarters of the physicians in the study said that they often obtain 
information from national guidelines in order to learn about using a new somatic genetic 
test (Table 4). Peer-reviewed medical literature was the second most common source of 
information (66% said they often and 29% said they sometimes obtained information 
from literature). Most physicians said that they never or rarely obtain information from 
the test manufacturer or drug company website (32% and 44%, respectfully), test 
manufacturer or drug company representative (38% and 15%, respectfully), and FDA 
package insert (27% and 39%, respectfully). In addition, many physicians reported they 
rarely obtain information from local colleagues (28%) or foundation or government 




None of the physician demographic characteristics were associated with recommending 
EGFR testing (Table 5).  
 
Who owns the practice was associated with recommending EGFR testing, with HMO, 
health plan, or insurance company ownership having the highest percentage of 
physicians recommending EGFR testing, followed by a university or medical school and 
one or more physicians or a physician-owned corporation (100%, 97%, and 97%, 
respectfully; p=0.080) (Table 6).  
 
Physicians who said the test predicting toxicity from specific treatments had a low or 
high impact on their decision to request genetic testing recommended EGFR testing more 
than those who said toxicity from specific treatments had only a moderate impact 
(p=0.071) (Table 7). Low impact of a patient requesting/inquiring about a test on the 
decision to recommend genetic testing coincided with recommending EGFR testing more 
than moderate or high impact of patient requests/inquiries on decision-making 
(p=0.037). Physicians who reported that they rarely obtain information from peer-
reviewed medical literature had the lowest percentage recommending EGFR testing 
compared to those who sometimes or often obtained information from this source (83% 




Physicians who graduated from a medical school outside of the U.S./Canada said that 
they would request ERCC1 testing more than those who graduated from a U.S./Canadian 
medical school (p=0.103) (Table 9).  
 
Solo practices and single specialty groups had the highest percentage of physicians 
recommending ERCC1 testing among the practice types (20% and 16%, respectfully; 
p=0.001) (Table 10). Who owns the practice also was associated with recommendation 
of ERCC1 testing, with university or medical school and one or more physicians or a 
physician-owned corporation having the highest percentage of physicians recommending 
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ERCC1 testing among all ownership types (13% and 16%, respectfully; p=0.073). 
Change in income as a result of ordering more genetic testing was also associated with 
recommendation of ERCC1 testing – physicians who said that ordering more genetic 
testing would likely increase their income recommended ERCC1 testing the most 
compared to those who said that ordering more genetic testing would likely decrease 
their income or not change their income (29% compared to 13% and 9%, respectfully; 
p=0.045). In addition, how the ERCC1 testing is usually requested or ordered in the 
practice was highly associated with whether the physician recommended ERCC1 testing -
- physicians reporting that another surgeon or physician orders the test recommended 
ERCC1 testing the most compared to physicians who reported that they have never 
ordered/requested ERCC1 testing or physicians that said another oncologist orders 
ERCC1 testing (60% compared to 0% and 0%, respectfully; p<0.001).   
 
Physicians who obtained information sometimes or often from local colleagues, 
national/international experts, national guidelines, and foundation or government 
websites recommended ERCC1testing more than those who never or rarely obtained 
information from these sources (p=0.062, p=0.037, p=0.041, and p=0.086, 
respectfully) (Table 12). Those who never or rarely reported obtaining information from 
test manufacturers or drug company websites recommended ERCC1 testing more than 
those who often obtained information from these sources (p=0.0260).  
 
Recommendation of Erlotinib 
 
Physician characteristics associated with Erlotinib are shown in Table 13. Physicians who 
chose Erlotinib as first-line regimen were younger and had less years since graduation 
from medical school compared to those who chose another treatment (p=0.008 and 
p=0.011, respectfully). Whether or not the physician graduated from a U.S./Canadian 
medical school was also associated with treatment choice, with 91% of those who did 
graduate from a U.S./Canadian medical school choosing Erlotinib compared to 83% of 
those who graduated from a medical school outside of the U.S. or Canada (p=0.068). 
Race/ethnicity was also associated with choice of Erlotinib, with 91% of Asian and Non-
Hispanic white physicians choosing Erlotinib as the first-line regimen while only 70% of 
‘Other’ races (non-Hispanic black, Native Hawaiian, other race, and multiracial) chose 
Erlotinib (p=0.021).  
 
Practice characteristics associated with first-line regimen recommendation only included 
practice type – physicians who had a solo practice were the least likely to recommend 
Erlotinib (70%) while single and multi-specialty groups and other practice types were 
the most likely to recommend Erlotinib (89%, 90%, and 97%, respectively; p=0.013) 
(Table 14).  
 
Physicians who said that whether or not local or national guidelines have been issued on 
test use had a high impact on their decision to request somatic genetic testing were more 
likely to choose Erlotinib compared to those who said national guidelines had a low 
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impact (92% and 78%, respectfully; p=0.066) (Table 15). Those who said they often 
obtain information from local colleagues, national/international experts, national 
guidelines, or foundation or government websites chose Erlotinib as first-line regimen 
more than those who never obtained information from these sources (p=0.062, 
p=0.037, p=0.041, and p=0.086, respectfully) (Table 16). On the other hand, those 
who say they often obtain information from test manufacturers or drug company 
websites chose Erlotinib the least compared to those who said they never or rarely use 
the source (p=0.026).  
 
After adjusting for physician demographic characteristics, practice characteristics and 
preferences/beliefs, gender, age, race, practice type, impact of national guidelines on 
decision to request testing, and obtaining information from national/international 
experts on new somatic genetic testing all remained significantly associated with choice 
of Erlotinib as first-line regimen (Table 17). Male physicians have a higher odds of 
choosing Erlotinib as first-line regimen compared to females (OR=2.75; 95% 
CI=[1.07,7.05]; p=0.035). A one year increase in age decreases the odds of choosing 
Erlotinib by 7% (OR=0.93; 95% CI=[0.89, 0.98]; p=0.005). Physicians who identify as 
non-Hispanic black, Native Hawaiian, other race, or multiracial have a 73% decrease in 
odds of choosing Erlotinib as first-line regimen compared to white physicians (OR=0.27; 
95% CI=[0.09, 0.77]; p=0.014). Those who graduated from a U.S./Canadian medical 
school have 2.36 times the odds of choosing Erlotinib compared to those who graduated 
from a medical school outside of the U.S./Canada (OR=2.36; 95% CI=[0.89, 6.26]; 
p=0.088). Physicians who believe that local or national guidelines issued on testing have 
a higher impact on the decision to request genetic testing have a higher odds of choosing 
Erlotinib compared to those who believe it has a lower impact (OR=2.07; 95% 
CI=[1.12, 3.871]; p=0.020). In addition, physicians who obtain information from 
national/international experts more often have a higher odds of choosing Erlotinib 
compared to those who obtain information from national/international experts less often 




Most studies have been focused on patient characteristics, preferences, and knowledge of 
genetic testing and treatment decision-making. Although patient characteristics are 
important, the role of physician characteristics and preferences in decision-making has 
been overlooked. In the case of NSCLC, where substantial evidence and recommendation 
from guidelines exist on the use of EGFR testing and first-line treatment with Erlotinib, 
variation in use is concerning. The results of the study offer important insight into the 
provider perspective of decision-making in genetic testing and treatment 
recommendation.  
 
In generalizing implications from this study, two fundamental assumptions become 
necessary: first, beliefs about therapy reveal knowledge about therapy; and second, 
beliefs about therapy influence actual practice.26 Given these assumptions, the present 
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study supports the notion that sources of information and perceived impact of sources 
plays a substantial role in both the likelihood of genetic testing usage and 
recommendation of targeted therapy. In our study sample, physicians who obtained 
more information from ‘credible’ sources, such as national guidelines and peer-reviewed 
medical literature, were more likely to choose appropriate testing (EGFR testing) and 
properly recommend first-line treatment with Erlotinib given a patient with an EGFR 
mutation. On the other hand, physicians who obtained information from less ‘credible’ 
sources, such as drug company websites or test manufacturers, were less likely to 
recommend the proper treatment. Interestingly, physicians who reported obtaining 
information from more ‘credible’ sources, such as national guidelines and local 
colleagues, also reported higher use of ERCC1 testing, although national guidelines do 
not support its use. This may reflect the complexity and sheer magnitude of information 
on genetic testing and new therapies, and the difficulty for physicians in sorting through 
information and choosing evidence-based findings/recommendations to incorporate in 
practice. Overall, it can be inferred that the variation seen in testing and treatment in 
patients with NSCLC is largely due to the difference in knowledge of physicians, which is 
itself a result of the sources of information used and the perceived impact of those and 
other sources. These results are consistent with studies that have shown physicians’ self-
reported deficits in knowledge of genetic testing and guidelines.32,33,34,35,36 Moreover, the 
implications that follow these findings include the importance of considering the content 
and format of reports/guidelines to clinicians and the need for easily accessible 
interfaces that provide the knowledge and support for clinical decisions.  
 
In terms of demographic characteristics, younger physicians and those who have less 
years since graduation from medical school, two characteristics which are likely related, 
recommended Erlotinib as first-line regimen more than older physicians and those who 
have been out of medical school for longer. This may echo the changes in medical 
education and access to and/or familiarity with research databases and other sources of 
information. In terms of practice characteristics, the finding that physicians’ with solo 
practices’ use ERCC1 testing more and recommend Erlotinib less than other practice 
types can be said to further highlight the importance of knowledge – being in a solo 
practice limits the transfer of knowledge between physicians and others in the health 
system that is often present in a multi-specialty group or some larger network. This 
interpretation would further emphasize the importance of adequate knowledge, and of 




Although the results allow us to draw significant conclusions, there are some limitations 
to this study. An imputed data set was used for analysis, due to the missing responses for 
important variables, and so the validity of those responses may be questionable. Further 
analysis could have involved more than one type of imputed dataset and combined the 
results of each dataset to form conclusions from the final models. Moreover, the study 
results are based on self-reported indicators, and therefore actual use of testing and 
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treatment recommendation may not coincide with physician responses. Further research 
is needed with both physicians’ self-reported indicators and actual practice patterns.  
 
Sub-specialty of a physician may play a role in familiarity with proper testing and 
treatment recommendation, but the study was unable to perform meaningful 
comparisons due to the low number of physicians with a sub-specialty. However, it is 
more likely that patients with NSCLC will be under the care of general oncologists than 
specialized oncologists.  
 
It is also possible that differences in guideline recommendations between professional 
organizations can play a role in some of the practice variability. In addition, physicians 
who completed this survey may be more interested/involved in research, and therefore 
have more knowledge of genetic testing and treatment choices than those who did not 
participate. This would, however, only further highlight the importance of the 




Summary of findings  
 
Failing to be tested or to receive proper treatment may adversely affect patient outcomes 
by compromising access to treatment that is associated with an overall survival benefit 
and superior quality of life. Ideally, all patients who are fit for treatment of advanced 
disease should undergo EGFR mutation testing in a timely manner and subsequently 
receive appropriate therapy so as to not delay first-line treatment choices and, therefore, 
higher quality outcomes. Thus, the identification of practice patterns and predictors of 
genetic testing and targeted therapy use are important in helping us move toward the 
goal of properly testing and treating suitable patients. The results of this study have 
highlighted the importance of information sources and physicians’ knowledge of novel 
testing and treatment recommendations. In particular, the variation in EGFR testing and 
subsequent recommendation of appropriate therapy in the management of NSCLC may 
be due to physicians’ attitudes toward the impact of information sources and consequent 
knowledge attained from these sources. It is important that physicians follow national 
guidelines in order for patients to have the best possible outcomes; efforts should be 
directed to improving physicians’ incorporation of guideline recommendations into their 
practice.  
 
Implications & Recommendations 
 
There will be an expanded need for physicians, particularly oncologists, knowledgeable 
in cancer genetics and novel treatments. Physicians must be aware of and understand the 
latest evidence-based guidelines for diagnosis and care, and must discuss test results and 
treatment recommendations with the patients. This will require new curricula, training, 
and facile knowledge transfer.37  
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To start, an easy checklist for oncologists dealing with advanced NSCLC patients may 
help ensure all patients receive testing and results prior to treatment recommendation. 
In terms of education, an annual conference or webinar could be used to update and/or 
tests physicians on the latest findings and recommendations in the specialty. This can be 
something established by national or professional associations, with the opportunity for 
physicians to count their completion of the conference/webinar toward a CME credit.  
 
Education alone does not necessarily translate into adoption of appropriate practices. 
Additional research is needed to further characterize contextual factors influencing the 
incorporation of genetic testing and management into clinical practice, and the 


































Table	  1.	  	  Description	  of	  the	  physician	  sample	  characteristics.	  	  	  
Characteristic	   N	  (%)*	  
Race/ethnicity	   	  
	  	  	  	  	  Non-­‐Hispanic	  White	   237	  (66.4)	  
	  	  	  	  	  Asian	   	  	  82	  (23.0)	  
	  	  	  	  	  Other†	   32	  (9.0)	  
	  	  	  	  	  Unknown	   	  	  6	  (1.7)	  
Age	  (years)	   	  
	  	  	  	  	  Mean	  ±	  SD	   54.00	  ±	  9.40	  
	  	  	  	  	  Median	  (Range)	   54.00	  (36,	  82)	  
Years	  since	  graduation,	  	   	  
	  	  	  	  	  Mean	  ±	  SD	   27.73	  ±	  9.71	  
	  	  	  	  	  Median	  (Range)	   28.00	  (8,	  55)	  
Sex	   	  
	  	  	  	  	  Male	   	  	  	  	  	  	  	  	  267	  (74.8)	  
	  	  	  	  	  Female	   90	  (25.2)	  
Graduation	  from	  U.S./Canadian	  
medical	  school	  	  
	  
	  	  	  	  	  Yes	   272	  (76.2)	  
	  	  	  	  	  No	   85	  (23.8)	  
Specialty	   	  
	  	  	  	  	  Hematology	   7	  (2.0)	  
	  	  	  	  	  Oncology	   224	  (63.3)	  
	  	  	  	  	  Hematology	  and	  Oncology	  	   108	  (30.5)	  
	  	  	  	  	  Specialized	  Hem/Onc	  (Lung)	   4	  (1.1)	  
	  	  	  	  	  Specialized	  Hem/Onc	  (Other)	   11	  (3.1)	  
Involvement	  with	  teaching	  
medical	  students/residents	  
	  
	  	  	  	  	  Yes	   168	  (47.1)	  
	  	  	  	  	  No	   189	  (52.9)	  
*	  Numbers	  may	  not	  sum	  to	  357	  due	  to	  missing	  data,	  and	  percentages	  may	  not	  sum	  to	  100%	  
due	  to	  rounding.	  












Table	  2.	  	  Description	  of	  the	  physician	  sample	  practice	  characteristics.	  	  
Characteristic	   N	  (%)*	  
Practice	  type	   	  
	  	  	  	  	  Solo	  practice	   27	  (7.6)	  
	  	  	  	  	  Single	  specialty	  group	   	  	  138	  (38.7)	  
	  	  	  	  	  Multi-­‐specialty	  group	   147	  (41.2)	  
	  	  	  	  	  Other	   	  	  45	  (12.6)	  
%	  PTs	  with	  lung	  cancer	   	  
	  	  	  	  	  Mean	  ±	  SD	   29.23	  ±	  27.44	  
	  	  	  	  	  Median	  (Range)	   19.44	  (0,	  100)	  
Paid	  by	  salary	  for	  clinical	  work	  in	  2011?	   	  
	  	  	  	  	  Yes	   	  	  	  	  	  	  	  	  245	  (68.6)	  
	  	  	  	  	  No	   112	  (31.4)	  
Best	  describes	  personal	  clinical	  income	  	   	  
	  	  	  	  	  Exclusively	  fee-­‐for-­‐service	   	  	  	  	  	  	  	  	  52	  (46.4)	  
	  	  	  	  	  Predominantly	  fee-­‐for-­‐service	   	  	  	  	  	  	  	  	  41	  (36.6)	  
	  	  	  	  	  Equal	  mix	  of	  fee-­‐for-­‐service	  &	  capitation	   	  	  	  	  	  	  	  	  16	  (14.3)	  
	  	  	  	  	  Predominantly	  capitation	   	  	  	  	  	  	  	  	  2	  (1.8)	  
	  	  	  	  	  Exclusively	  capitation	   	  	  	  	  	  	  	  1	  (0.9)	  
Who	  owns	  the	  practice	   	  
	  	  	  	  	  University	  or	  medical	  school	   58	  (16.3)	  
	  	  	  	  	  Federal,	  state,	  or	  local	  government	   16	  (4.5)	  
	  	  	  	  	  1	  or	  1+	  physicians/physician-­‐owned	  corp	   157	  (44.0)	  
	  	  	  	  	  A	  hospital	   66	  (18.5)	  
	  	  	  	  	  HMO,	  health	  plan,	  or	  insurance	  company	   43	  (12.0)	  
	  	  	  	  	  Some	  other	  type	  of	  owner	   17	  (4.8)	  
	  	  	  	  	  Don’t	  know	   0	  (0.0)	  
How,	  if	  at	  all,	  income	  is	  mostly	  likely	  to	  change	  
as	  a	  result	  of	  prescribing/administering	  more	  
chemotherapy	  
	  
	  	  	  	  	  Likely	  to	  decrease	   32	  (9.0)	  
	  	  	  	  	  Not	  likely	  to	  change	   249	  (69.8)	  
	  	  	  	  	  Likely	  to	  decrease	  	   57	  (16.0)	  
	  	  	  	  	  Don’t	  know	   19	  (5.3)	  
How,	  if	  at	  all,	  income	  is	  mostly	  likely	  to	  change	  
as	  a	  result	  of	  ordering	  more	  genetic	  testing	  
	  
	  	  	  	  	  Likely	  to	  decrease	   8	  (2.2)	  
	  	  	  	  	  Not	  likely	  to	  change	   313	  (87.7)	  
	  	  	  	  	  Likely	  to	  increase	  	   21	  (5.9)	  
	  	  	  	  	  Don’t	  know	   15	  (4.2)	  
*	  Numbers	  may	  not	  sum	  to	  357	  due	  to	  missing	  data,	  and	  percentages	  may	  not	  sum	  to	  100%	  
due	  to	  rounding.	  
†	  If	  not	  paid	  by	  salary	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Table	  3.	  Description	  of	  physician	  preferences:	  impact	  of	  variables	  on	  requesting	  somatic	  genetic	  
testing.	  	  
Characteristic	   N	  (%)*	  
Whether	  or	  not	  local	  or	  national	  
guidelines	  have	  been	  issued	  on	  test	  
use	  
	  
	  	  	  	  	  Low	  impact	   20	  (5.6)	  
	  	  	  	  	  Moderate	  impact	   108	  (30.3)	  
	  	  	  	  	  High	  impact	   229	  (64.2)	  
FDA	  alerts	  about	  availability	  of	  test	   	  
	  	  	  	  	  Low	  impact	   97	  (27.2)	  
	  	  	  	  	  Moderate	  impact	   165	  (46.2)	  
	  	  	  	  	  High	  impact	   95	  (26.6)	  
Test	  sensitivity	  and	  specificity	   	  
	  	  	  	  	  Low	  impact	   14	  (3.9)	  
	  	  	  	  	  Moderate	  impact	   125	  (35.0)	  
	  	  	  	  	  High	  impact	   218	  (61.1)	  
Prevalence	  of	  genetic	  alteration	   	  
	  	  	  	  	  Low	  impact	   50	  (14.0)	  
	  	  	  	  	  Moderate	  impact	   181	  (50.7)	  
	  	  	  	  	  High	  impact	   126	  (35.3)	  
Test	  predicts	  clinical	  benefit	  from	  
specific	  treatments	  
	  
	  	  	  	  	  Low	  impact	   1	  (0.3)	  
	  	  	  	  	  Moderate	  impact	   37	  (10.4)	  
	  	  	  	  	  High	  impact	   319	  (89.4)	  
Test	  predicts	  toxicity	  from	  specific	  
treatments	  
	  
	  	  	  	  	  Low	  impact	   24	  (6.7)	  
	  	  	  	  	  Moderate	  impact	   151	  (42.3)	  
	  	  	  	  	  High	  impact	   182	  (51.0)	  
Test	  predicts	  prognostic	  information	   	  
	  	  	  	  	  Low	  impact	   21	  (5.9)	  
	  	  	  	  	  Moderate	  impact	   150	  (42.0)	  
	  	  	  	  	  High	  impact	   186	  (52.1)	  
Patient	  requests/inquires	  about	  test	   	  
	  	  	  	  	  Low	  impact	   97	  (27.2)	  
	  	  	  	  	  Moderate	  impact	   206	  (	  57.7)	  
	  	  	  	  	  High	  impact	   54	  (15.1)	  
*	  Numbers	  may	  not	  sum	  to	  357	  due	  to	  missing	  data,	  and	  percentages	  may	  not	  sum	  to	  100%	  




Table	  4.	  Description	  of	  physician	  sources	  of	  information:	  how	  often	  they	  obtain	  information	  
from	  the	  following	  sources	  in	  order	  to	  learn	  about	  using	  a	  new	  somatic	  genetic	  test.	  
Characteristic	   N	  (%)*	  
Local	  colleagues	   	  
	  	  	  	  	  Never	   27	  (7.6)	  
	  	  	  	  	  Rarely	   101	  (28.3)	  
	  	  	  	  	  Sometimes	   163	  (45.7)	  
	  	  	  	  	  Often	   66	  (18.5)	  
National/international	  experts	   	  
	  	  	  	  	  Never	   9	  (2.5)	  
	  	  	  	  	  Rarely	   43	  (12.0)	  
	  	  	  	  	  Sometimes	   141	  (39.5)	  
	  	  	  	  	  Often	   164	  (45.9)	  
Test	  manufacturer	  or	  drug	  company	  
representative	  
	  
	  	  	  	  	  Never	   53	  (14.9)	  
	  	  	  	  	  Rarely	   134	  (37.5)	  
	  	  	  	  	  Sometimes	   139	  (38.9)	  
	  	  	  	  	  Often	   31	  (8.7)	  
National	  guidelines	   	  
	  	  	  	  	  Never	   4	  (1.1)	  
	  	  	  	  	  Rarely	   12	  (3.4)	  
	  	  	  	  	  Sometimes	   	  75	  (21.0)	  
	  	  	  	  	  Often	   266	  (74.5)	  
Scientific	  meetings	  and	  conferences	   	  
	  	  	  	  	  Never	   1	  (0.3)	  
	  	  	  	  	  Rarely	   22	  (6.2)	  
	  	  	  	  	  Sometimes	   121	  (33.9)	  
	  	  	  	  	  Often	   213	  (59.7)	  
Peer-­‐reviewed	  medical	  literature	   	  
	  	  	  	  	  Never	   4	  (1.1)	  
	  	  	  	  	  Rarely	   13	  (3.6)	  
	  	  	  	  	  Sometimes	   104	  (29.1)	  
	  	  	  	  	  Often	   236	  (66.1)	  
Foundation	  or	  government	  website	   	  
	  	  	  	  	  Never	   19	  (5.3)	  
	  	  	  	  	  Rarely	   90	  (25.2)	  
	  	  	  	  	  Sometimes	   142	  (39.8)	  




	  	  	  	  	  Never	   25	  (7.0)	  
	  	  	  	  	  Rarely	   55	  (15.4)	  
	  	  	  	  	  Sometimes	   111	  (31.1)	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  Often	   166	  (46.5)	  
Test	  manufacturer	  or	  drug	  company	  
websites	  
	  
	  	  	  	  	  Never	   114	  (31.9)	  
	  	  	  	  	  Rarely	   158	  (44.3)	  
	  	  	  	  	  Sometimes	   77	  (21.6)	  
	  	  	  	  	  Often	   8	  (2.2)	  
FDA	  package	  insert	   	  
	  	  	  	  	  Never	   97	  (27.2)	  
	  	  	  	  	  Rarely	   139	  (38.9)	  
	  	  	  	  	  Sometimes	   101	  (28.3)	  
	  	  	  	  	  Often	   20	  (5.6)	  
*	  Numbers	  may	  not	  sum	  to	  357	  due	  to	  missing	  data,	  and	  percentages	  may	  not	  sum	  to	  100%	  






























Table	  5.	  	  Unadjusted	  associations	  between	  physician	  characteristics	  and	  respondents	  who	  
reported	  they	  were	  ‘Very	  Likely’	  or	  ‘Somewhat	  Likely’	  to	  order	  EGFR.	  





Race/ethnicity	   	   	   0.760	  
	  	  	  	  	  Non-­‐Hispanic	  White	   209	   95.2	   	  
	  	  	  	  	  Asian	   70	   97.1	   	  
	  	  	  	  	  Other†	   30	   93.3	   	  
	  	  	  	  	  Unknown	   6	   100.0	   	  
Age	  (years),	  mean	  ±	  SD	   	   	   0.397	  
	  	  	  	  	  Very/Somewhat	  Likely	   54.27	  ±	  9.29	   	   	  
	  	  	  	  	  Very/Somewhat	  Unlikely	   56.43	  ±	  9.65	   	   	  
Years	  since	  graduation,	  mean	  ±	  SD	   	   	   0.490	  
	  	  	  	  	  Very/Somewhat	  Likely	   28.12	  ±	  9.55	   	   	  
	  	  	  	  	  Very/Somewhat	  Unlikely	   29.93	  ±	  9.84	   	   	  
Sex	   	   	   1.000	  
	  	  	  	  	  Male	   236	   95.3	   	  
	  	  	  	  	  Female	   79	   96.2	   	  
Graduation	  from	  U.S./Canadian	  
medical	  school	  	  
	   	   0.347	  
	  	  	  	  	  Yes	   237	   96.2	   	  
	  	  	  	  	  No	   78	   93.6	   	  
Specialty	   	   	   0.815	  
	  	  	  	  	  Hematology	   5	   100.0	   	  
	  	  	  	  	  Oncology	   194	   94.9	   	  
	  	  	  	  	  Hematology	  and	  Oncology	  	   106	   97.1	   	  
	  	  	  	  	  Specialized	  Hem/Onc	  (Lung)	   4	   100	   	  
	  	  	  	  	  Specialized	  Hem/Onc	  (Other)	   3	   100	   	  
Involvement	  with	  teaching	  
medical	  students/residents	  
	   	   0.564	  
	  	  	  	  	  Yes	   136	   96.3	   	  
	  	  	  	  	  No	   179	   95.0	   	  
*	  Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data.	  









Table	  6.	  Unadjusted	  associations	  between	  practice	  characteristics	  and	  respondents	  who	  
reported	  they	  were	  ‘Very	  Likely’	  or	  ‘Somewhat	  Likely’	  to	  order	  EGFR.	  
Characteristic	   N*	   %	  Very/Somewhat	  Likely	  (EGFR)	   p
†	  
Practice	  type	   	   	   0.340	  
	  	  	  	  	  Solo	  practice	   27	   92.6	   	  
	  	  	  	  	  Single	  specialty	  group	   130	   96.9	   	  
	  	  	  	  	  Multi-­‐specialty	  group	   122	   95.9	   	  
	  	  	  	  	  Other	   36	   91.7	   	  
%	  PTs	  with	  lung	  cancer,	  mean	  ±	  SD	   	   	   0.316	  
	  	  	  	  	  Very/Somewhat	  Likely	   29.73	  ±	  27.44	   	   	  
	  	  	  	  	  Very/Somewhat	  Unlikely	   22.19	  ±	  27.35	   	   	  
Paid	  by	  salary	  for	  clinical	  work	  in	  2011?	   	   	   0.154	  
	  	  	  	  	  Yes	   210	   94.3	   	  
	  	  	  	  	  No	   105	   98.1	   	  
Best	  describes	  personal	  clinical	  income†	   	   	   1.000	  
	  	  	  	  	  Exclusively	  fee-­‐for-­‐service	   50	   98.0	   	  
	  	  	  	  	  Predominantly	  fee-­‐for-­‐service	   37	   97.3	   	  
	  	  	  	  	  Equal	  mix	  of	  fee-­‐for-­‐service	  &	  capitation	   15	   100.0	   	  
	  	  	  	  	  Predominantly	  capitation	   2	   100.0	   	  
	  	  	  	  	  Exclusively	  capitation	   1	   100.0	   	  
Who	  owns	  the	  practice	   	   	   0.080	  
	  	  	  	  	  University	  or	  medical	  school	   36	   97.2	   	  
	  	  	  	  	  Federal,	  state,	  or	  local	  government	   14	   92.9	   	  
	  	  	  	  	  1	  or	  1+	  physicians/physician-­‐owned	  corp.	   152	   96.7	   	  
	  	  	  	  	  A	  hospital	   59	   91.5	   	  
	  	  	  	  	  HMO,	  health	  plan,	  or	  insurance	  company	   41	   100.0	   	  
	  	  	  	  	  Some	  other	  type	  of	  owner	   13	   84.6	   	  
	  	  	  	  	  Don’t	  know	   0	   0.0	   	  
How,	  if	  at	  all,	  income	  is	  mostly	  likely	  to	  
change	  as	  a	  result	  of	  
prescribing/administering	  more	  
chemotherapy	  
	   	   0.877	  
	  	  	  	  	  Likely	  to	  decrease	   30	   96.7	   	  
	  	  	  	  	  Not	  likely	  to	  change	   211	   95.7	   	  
	  	  	  	  	  Likely	  to	  decrease	  	   57	   94.7	   	  
	  	  	  	  	  Don’t	  know	   17	   94.1	   	  
How,	  if	  at	  all,	  income	  is	  mostly	  likely	  to	  
change	  as	  a	  result	  of	  ordering	  more	  genetic	  
testing	  
	   	   0.188	  
	  	  	  	  	  Likely	  to	  decrease	   8	   100.0	   	  
	  	  	  	  	  Not	  likely	  to	  change	   279	   96.1	   	  
	  	  	  	  	  Likely	  to	  increase	   16	   87.5	   	  
	  	  	  	  	  Don’t	  know	   12	   91.7	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How	  the	  	  test	  is	  usually	  requested	  or	  
ordered	  in	  your	  practice	  
	   	   0.656	  
	  	  	  	  	  Self	   285	   95.1	   	  
	  	  	  	  	  Another	  oncologist	   0	   0.0	   	  
	  	  	  	  	  Pathologist	   28	   100.0	   	  
	  	  	  	  	  Surgeon	  or	  other	  physician	   1	   100.0	   	  
	  	  	  	  	  This	  test	  has	  not	  been	  ordered/requested	   1	   100.0	   	  
*	  Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data.	  































Table	  7.	  	  Unadjusted	  associations	  between	  impact	  of	  sources	  on	  requesting	  genetic	  testing	  and	  
respondents	  who	  reported	  they	  were	  ‘Very	  Likely’	  or	  ‘Somewhat	  Likely’	  to	  order	  EGFR.	  





Whether	  or	  not	  local	  or	  national	  
guidelines	  have	  been	  issued	  on	  test	  use	  
	   	   0.802	  
	  	  	  	  	  Low	  impact	   17	   94.1	   	  
	  	  	  	  	  Moderate	  impact	   92	   95.7	   	  
	  	  	  	  	  High	  impact	   206	   95.6	   	  
FDA	  alerts	  about	  availability	  of	  test	   	   	   0.646	  
	  	  	  	  	  Low	  impact	   85	   94.1	   	  
	  	  	  	  	  Moderate	  impact	   144	   96.5	   	  
	  	  	  	  	  High	  impact	   86	   95.4	   	  
Test	  sensitivity	  and	  specificity	   	   	   0.669	  
	  	  	  	  	  Low	  impact	   13	   92.3	   	  
	  	  	  	  	  Moderate	  impact	   111	   95.5	   	  
	  	  	  	  	  High	  impact	   191	   95.8	   	  
Prevalence	  of	  genetic	  alteration	   	   	   0.264	  
	  	  	  	  	  Low	  impact	   44	   100.0	   	  
	  	  	  	  	  Moderate	  impact	   157	   94.3	   	  
	  	  	  	  	  High	  impact	   114	   95.6	   	  
Test	  predicts	  clinical	  benefit	  from	  
specific	  treatments	  
	   	   1.000	  
	  	  	  	  	  Low	  impact	   1	   100.0	   	  
	  	  	  	  	  Moderate	  impact	   29	   96.6	   	  
	  	  	  	  	  High	  impact	   285	   95.4	   	  
Test	  predicts	  toxicity	  from	  specific	  
treatments	  
	   	   0.071	  
	  	  	  	  	  Low	  impact	   22	   100.0	   	  
	  	  	  	  	  Moderate	  impact	   134	   92.5	   	  
	  	  	  	  	  High	  impact	   159	   97.5	   	  
Test	  predicts	  prognostic	  information	   	   	   0.470	  
	  	  	  	  	  Low	  impact	   20	   100.0	   	  
	  	  	  	  	  Moderate	  impact	   132	   96.2	   	  
	  	  	  	  	  High	  impact	   163	   94.5	   	  
Patient	  requests/inquires	  about	  test	   	   	   0.037	  
	  	  	  	  	  Low	  impact	   90	   97.8	   	  
	  	  	  	  	  Moderate	  impact	   179	   94.4	   	  
	  	  	  	  	  High	  impact	   46	   95.7	   	  
*	  Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data.	  
†	  P-­‐value	  for	  χ2	  test	  or	  Fisher’s	  Exact	  test,	  where	  appropriate.	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Table	  8.	  Unadjusted	  associations	  between	  how	  often	  physicians	  obtain	  information	  from	  the	  
following	  sources	  in	  order	  to	  learn	  about	  using	  a	  new	  somatic	  genetic	  test	  and	  respondents	  
who	  reported	  they	  were	  ‘Very	  Likely’	  or	  ‘Somewhat	  Likely’	  to	  order	  EGFR.	  
Characteristic	   N*	   %	  Very/Somewhat	  Likely	  (EGFR)	   p
†	  
Local	  colleagues	   	   	   0.972	  
	  	  	  	  	  Never	   25	   96.0	   	  
	  	  	  	  	  Rarely	   90	   94.4	   	  
	  	  	  	  	  Sometimes	   148	   96.0	   	  
	  	  	  	  	  Often	   52	   96.2	   	  
National/international	  experts	   	   	   0.381	  
	  	  	  	  	  Never	   9	   100.0	   	  
	  	  	  	  	  Rarely	   35	   94.3	   	  
	  	  	  	  	  Sometimes	   126	   97.6	   	  
	  	  	  	  	  Often	   145	   93.8	   	  
Test	  manufacturer	  or	  drug	  company	  
representative	  
	   	   0.132	  
	  	  	  	  	  Never	   44	   97.7	   	  
	  	  	  	  	  Rarely	   117	   95.7	   	  
	  	  	  	  	  Sometimes	   124	   96.8	   	  
	  	  	  	  	  Often	   30	   86.7	   	  
National	  guidelines	   	   	   0.846	  
	  	  	  	  	  Never	   4	   100.0	   	  
	  	  	  	  	  Rarely	   7	   100.0	   	  
	  	  	  	  	  Sometimes	   	  69	   97.1	   	  
	  	  	  	  	  Often	   235	   94.9	   	  
Scientific	  meetings	  and	  conferences	   	   	   0.614	  
	  	  	  	  	  Never	   1	   100.0	   	  
	  	  	  	  	  Rarely	   20	   100.0	   	  
	  	  	  	  	  Sometimes	   112	   96.4	   	  
	  	  	  	  	  Often	   182	   94.5	   	  
Peer-­‐reviewed	  medical	  literature	   	   	   0.068	  
	  	  	  	  	  Never	   4	   100.0	   	  
	  	  	  	  	  Rarely	   12	   83.3	   	  
	  	  	  	  	  Sometimes	   92	   98.9	   	  
	  	  	  	  	  Often	   207	   94.7	   	  
Foundation	  or	  government	  website	   	   	   0.340	  
	  	  	  	  	  Never	   17	   100.0	   	  
	  	  	  	  	  Rarely	   79	   96.2	   	  
	  	  	  	  	  Sometimes	   127	   92.9	   	  
	  	  	  	  	  Often	   92	   97.8	   	  
Evidence-­‐based,	  synthesized	  websites	   	   	   0.268	  
	  	  	  	  	  Never	   23	   91.3	   	  
	  	  	  	  	  Rarely	   49	   91.8	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  Sometimes	   97	   96.9	   	  
	  	  	  	  	  Often	   146	   96.6	   	  
Test	  manufacturer	  or	  drug	  company	  
websites	  
	   	   0.192	  
	  	  	  	  	  Never	   104	   98.1	   	  
	  	  	  	  	  Rarely	   137	   94.2	   	  
	  	  	  	  	  Sometimes	   67	   95.5	   	  
	  	  	  	  	  Often	   7	   85.7	   	  
FDA	  package	  insert	   	   	   0.575	  
	  	  	  	  	  Never	   88	   97.7	   	  
	  	  	  	  	  Rarely	   119	   95.0	   	  
	  	  	  	  	  Sometimes	   92	   94.6	   	  
	  	  	  	  	  Often	   16	   93.8	   	  
*	  Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data.	  



























Table	  9.	  	  Unadjusted	  associations	  between	  physician	  characteristics	  and	  respondents	  who	  
reported	  they	  were	  ‘Very	  Likely’	  or	  ‘Somewhat	  Likely’	  to	  order	  ERCC1.	  





Race/ethnicity	   	   	   0.578	  
	  	  	  	  	  Non-­‐Hispanic	  White	   169	   10.1	   	  
	  	  	  	  	  Asian	   58	   10.3	   	  
	  	  	  	  	  Other†	   22	   18.2	   	  
	  	  	  	  	  Unknown	   6	   0.0	   	  
Age	  (years),	  mean	  ±	  SD	   	   	   0.788	  
	  	  	  	  	  Very/Somewhat	  Likely	   53.56	  ±	  9.52	   	   	  
	  	  	  	  	  Very/Somewhat	  Unlikely	   54.06	  ±	  9.12	   	   	  
Years	  since	  graduation,	  mean	  ±	  SD	   	   	   0.853	  
	  	  	  	  	  Very/Somewhat	  Likely	   27.59	  ±	  9.83	   	   	  
	  	  	  	  	  Very/Somewhat	  Unlikely	   27.95	  ±	  9.33	   	   	  
Sex	   	   	   0.836	  
	  	  	  	  	  Male	   193	   10.4	   	  
	  	  	  	  	  Female	   62	   11.3	   	  
Graduation	  from	  U.S./Canadian	  
medical	  school	  	  
	   	   0.103	  
	  	  	  	  	  Yes	   193	   8.8	   	  
	  	  	  	  	  No	   62	   16.1	   	  
Specialty	   	   	   0.678	  
	  	  	  	  	  Hematology	   5	   20.0	   	  
	  	  	  	  	  Oncology	   162	   10.5	   	  
	  	  	  	  	  Hematology	  and	  Oncology	  	   81	   8.8	   	  
	  	  	  	  	  Specialized	  Hem/Onc	  (Lung)	   3	   0.0	   	  
	  	  	  	  	  Specialized	  Hem/Onc	  (Other)	   1	   0.0	   	  
Involvement	  with	  teaching	  medical	  
students/residents	  
	   	   0.850	  
	  	  	  	  	  Yes	   109	   11.0	   	  
	  	  	  	  	  No	   146	   10.3	   	  
*	  Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data.	  









Table	  10.	  Unadjusted	  associations	  between	  practice	  characteristics	  and	  respondents	  who	  
reported	  they	  were	  ‘Very	  Likely’	  or	  ‘Somewhat	  Likely’	  to	  order	  ERCC1.	  
Characteristic	   N*	   %	  Very/Somewhat	  Likely	  (ERCC1)	   p
†	  
Practice	  type	   	   	   0.001	  
	  	  	  	  	  Solo	  practice	   20	   20.0	   	  
	  	  	  	  	  Single	  specialty	  group	   108	   15.7	   	  
	  	  	  	  	  Multi-­‐specialty	  group	   98	   2.0	   	  
	  	  	  	  	  Other	   29	   13.8	   	  
%	  PTs	  with	  lung	  cancer,	  mean	  ±	  SD	   	   	   0.632	  
	  	  	  	  	  Yes	   171	   9.9	   	  
	  	  	  	  	  No	   84	   11.9	   	  
Paid	  by	  salary	  for	  clinical	  work	  in	  2011?	   	   	   0.877	  
	  	  	  	  	  Very/Somewhat	  Likely	   29.72	  ±	  27.88	   89.2	   	  
	  	  	  	  	  Very/Somewhat	  Unlikely	   25.24	  ±	  23.57	   88.6	   	  
Best	  describes	  personal	  clinical	  income†	   	   	   0.928	  
	  	  	  	  	  Exclusively	  fee-­‐for-­‐service	   41	   12.2	   	  
	  	  	  	  	  Predominantly	  fee-­‐for-­‐service	   28	   10.7	   	  
	  	  	  	  	  Equal	  mix	  of	  fee-­‐for-­‐service	  &	  capitation	   13	   15.4	   	  
	  	  	  	  	  Predominantly	  capitation	   1	   0.0	   	  
	  	  	  	  	  Exclusively	  capitation	   1	   0.0	   	  
Who	  owns	  the	  practice	   	   	   0.073	  
	  	  	  	  	  University	  or	  medical	  school	   32	   12.5	   	  
	  	  	  	  	  Federal,	  state,	  or	  local	  government	   10	   0.0	   	  
	  	  	  	  	  1	  or	  1+	  physicians/physician-­‐owned	  corp.	   120	   15.8	   	  
	  	  	  	  	  A	  hospital	   50	   8.0	   	  
	  	  	  	  	  HMO,	  health	  plan,	  or	  insurance	  company	   32	   0.0	   	  
	  	  	  	  	  Some	  other	  type	  of	  owner	   11	   0.0	   	  
	  	  	  	  	  Don’t	  know	   0	   0.0	   	  
How,	  if	  at	  all,	  income	  is	  mostly	  likely	  to	  
change	  as	  a	  result	  of	  
prescribing/administering	  more	  
chemotherapy	  
	   	   0.504	  
	  	  	  	  	  Likely	  to	  decrease	   8	   8.0	   	  
	  	  	  	  	  Not	  likely	  to	  change	   166	   10.8	   	  
	  	  	  	  	  Likely	  to	  decrease	  	   50	   8.0	   	  
	  	  	  	  	  Don’t	  know	   14	   21.4	   	  
How,	  if	  at	  all,	  income	  is	  mostly	  likely	  to	  
change	  as	  a	  result	  of	  ordering	  more	  genetic	  
testing	  
	   	   0.045	  
	  	  	  	  	  Likely	  to	  decrease	   8	   12.5	   	  
	  	  	  	  	  Not	  likely	  to	  change	   225	   8.9	   	  
	  	  	  	  	  Likely	  to	  increase	  	   14	   28.6	   	  
	  	  	  	  	  Don’t	  know	   8	   25.0	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How	  the	  	  test	  is	  usually	  requested	  or	  ordered	  
in	  your	  practice	  
	   	   <0.001	  
	  	  	  	  	  Self	   79	   27.9	   	  
	  	  	  	  	  Another	  oncologist	   6	   0.0	   	  
	  	  	  	  	  Pathologist	   7	   28.6	   	  
	  	  	  	  	  Surgeon	  or	  other	  physician	   5	   60.0	   	  
	  	  	  	  	  This	  test	  has	  not	  been	  ordered/requested	   158	   0.0	   	  
*	  Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data.	  






























Table	  11.	  	  Unadjusted	  associations	  between	  impact	  of	  variables	  on	  requesting	  somatic	  genetic	  
testing	  and	  respondents	  who	  reported	  they	  were	  ‘Very	  Likely’	  or	  ‘Somewhat	  Likely’	  to	  order	  
ERCC1.	  





Whether	  or	  not	  local	  or	  national	  
guidelines	  have	  been	  issued	  on	  test	  use	  
	   	   0.479	  
	  	  	  	  	  Low	  impact	   13	   15.4	   	  
	  	  	  	  	  Moderate	  impact	   74	   13.5	   	  
	  	  	  	  	  High	  impact	   168	   8.9	   	  
FDA	  alerts	  about	  availability	  of	  test	   	   	   0.560	  
	  	  	  	  	  Low	  impact	   64	   7.8	   	  
	  	  	  	  	  Moderate	  impact	   118	   12.7	   	  
	  	  	  	  	  High	  impact	   73	   9.6	   	  
Test	  sensitivity	  and	  specificity	   	   	   0.738	  
	  	  	  	  	  Low	  impact	   12	   8.3	   	  
	  	  	  	  	  Moderate	  impact	   87	   12.6	   	  
	  	  	  	  	  High	  impact	   156	   9.6	   	  
Prevalence	  of	  genetic	  alteration	   	   	   0.553	  
	  	  	  	  	  Low	  impact	   38	   13.2	   	  
	  	  	  	  	  Moderate	  impact	   129	   8.5	   	  
	  	  	  	  	  High	  impact	   88	   12.5	   	  
Test	  predicts	  clinical	  benefit	  from	  
specific	  treatments	  
	   	   0.750	  
	  	  	  	  	  Low	  impact	   1	   0.0	   	  
	  	  	  	  	  Moderate	  impact	   23	   13.0	   	  
	  	  	  	  	  High	  impact	   231	   10.4	   	  
Test	  predicts	  toxicity	  from	  specific	  
treatments	  
	   	   0.302	  
	  	  	  	  	  Low	  impact	   19	   21.1	   	  
	  	  	  	  	  Moderate	  impact	   106	   9.4	   	  
	  	  	  	  	  High	  impact	   130	   10.0	   	  
Test	  predicts	  prognostic	  information	   	   	   0.246	  
	  	  	  	  	  Low	  impact	   16	   0.0	   	  
	  	  	  	  	  Moderate	  impact	   116	   9.5	   	  
	  	  	  	  	  High	  impact	   123	   13.0	   	  
Patient	  requests/inquires	  about	  test	   	   	   0.525	  
	  	  	  	  	  Low	  impact	   70	   7.1	   	  
	  	  	  	  	  Moderate	  impact	   147	   11.6	   	  
	  	  	  	  	  High	  impact	   38	   13.2	   	  
*	  Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data.	  
†	  P-­‐value	  for	  χ2	  test	  or	  Fisher’s	  Exact	  test,	  where	  appropriate.	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Table	  12.	  	  Unadjusted	  associations	  between	  how	  often	  physicians	  obtain	  information	  from	  the	  
following	  sources	  in	  order	  to	  learn	  about	  using	  a	  new	  somatic	  genetic	  test	  and	  respondents	  
who	  reported	  they	  were	  ‘Very	  Likely’	  or	  ‘Somewhat	  Likely’	  to	  order	  ERCC1.	  
Characteristic	   N*	   %	  Very/Somewhat	  Likely	  (ERCC1)	   p
†	  
Local	  colleagues	   	   	   0.062	  
	  	  	  	  	  Never	   26	   73.1	   	  
	  	  	  	  	  Rarely	   90	   91.1	   	  
	  	  	  	  	  Sometimes	   149	   89.9	   	  
	  	  	  	  	  Often	   52	   90.4	   	  
National/international	  experts	   	   	   0.037	  
	  	  	  	  	  Never	   9	   55.6	   	  
	  	  	  	  	  Rarely	   36	   88.9	   	  
	  	  	  	  	  Sometimes	   127	   89.0	   	  
	  	  	  	  	  Often	   145	   91.0	   	  
Test	  manufacturer	  or	  drug	  company	  
representative	  
	   	   0.237	  
	  	  	  	  	  Never	   44	   93.2	   	  
	  	  	  	  	  Rarely	   118	   91.5	   	  
	  	  	  	  	  Sometimes	   125	   87.2	   	  
	  	  	  	  	  Often	   30	   80.0	   	  
National	  guidelines	   	   	   0.041	  
	  	  	  	  	  Never	   4	   50.0	   	  
	  	  	  	  	  Rarely	   8	   100.0	   	  
	  	  	  	  	  Sometimes	   	  69	   84.1	   	  
	  	  	  	  	  Often	   236	   90.7	   	  
Scientific	  meetings	  and	  conferences	   	   	   0.346	  
	  	  	  	  	  Never	   1	   100.0	   	  
	  	  	  	  	  Rarely	   20	   95.0	   	  
	  	  	  	  	  Sometimes	   114	   85.1	   	  
	  	  	  	  	  Often	   182	   90.7	   	  
Peer-­‐reviewed	  medical	  literature	   	   	   0.116	  
	  	  	  	  	  Never	   4	   50.0	   	  
	  	  	  	  	  Rarely	   12	   91.7	   	  
	  	  	  	  	  Sometimes	   94	   87.2	   	  
	  	  	  	  	  Often	   207	   90.3	   	  
Foundation	  or	  government	  website	   	   	   0.086	  
	  	  	  	  	  Never	   17	   70.6	   	  
	  	  	  	  	  Rarely	   80	   88.8	   	  
	  	  	  	  	  Sometimes	   127	   91.3	   	  
	  	  	  	  	  Often	   93	   89.3	   	  
Evidence-­‐based,	  synthesized	  websites	   	   	   0.425	  
	  	  	  	  	  Never	   23	   87.0	   	  
	  	  	  	  	  Rarely	   49	   83.7	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  Sometimes	   99	   87.9	   	  
	  	  	  	  	  Often	   146	   91.8	   	  
Test	  manufacturer	  or	  drug	  company	  
websites	  
	   	   0.026	  
	  	  	  	  	  Never	   104	   87.5	   	  
	  	  	  	  	  Rarely	   138	   94.2	   	  
	  	  	  	  	  Sometimes	   68	   82.4	   	  
	  	  	  	  	  Often	   7	   71.4	   	  
FDA	  package	  insert	   	   	   0.351	  
	  	  	  	  	  Never	   88	   88.6	   	  
	  	  	  	  	  Rarely	   121	   92.6	   	  
	  	  	  	  	  Sometimes	   92	   84.8	   	  
	  	  	  	  	  Often	   16	   87.5	   	  
*	  Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data.	  


























Table	  13.	  	  Unadjusted	  associations	  between	  physician	  characteristics	  and	  choice	  of	  Erlotinib	  as	  
first-­‐line	  regimen.	  





Race/ethnicity	   	   	   0.021	  
	  	  	  	  	  Non-­‐Hispanic	  white	   210	   90.5	   	  
	  	  	  	  	  Asian	   70	   91.4	   	  
	  	  	  	  	  Other†	   31	   71.0	   	  
	  	  	  	  	  Unknown	   6	   100.0	   	  
Age	  (years),	  mean	  ±	  SD	   	   	   0.008	  
	  	  	  	  	  Erlotinib	   53.88	  ±	  9.16	   	   	  
	  	  	  	  	  Other	   58.26	  ±	  9.46	   	   	  
Years	  since	  graduation,	  mean	  ±	  SD	   	   	   0.011	  
	  	  	  	  	  Erlotinib	   27.70	  ±	  9.36	   	   	  
	  	  	  	  	  Other	   32.06	  ±	  10.12	   	   	  
Sex	   	   	   0.597	  
	  	  	  	  	  Male	   238	   89.5	   	  
	  	  	  	  	  Female	   79	   87.3	   	  
Graduation	  from	  U.S./Canadian	  
medical	  school	  	  
	   	   0.068	  
	  	  	  	  	  Yes	   239	   90.8	   	  
	  	  	  	  	  No	   78	   83.3	   	  
Specialty	   	   	   0.634	  
	  	  	  	  	  Hematology	   5	   80.0	   	  
	  	  	  	  	  Oncology	   195	   90.3	   	  
	  	  	  	  	  Hematology	  and	  Oncology	  	   107	   86.9	   	  
	  	  	  	  	  Specialized	  Hem/Onc	  (Lung)	   4	   100	   	  
	  	  	  	  	  Specialized	  Hem/Onc	  (Other)	   3	   100	   	  
Involvement	  with	  teaching	  
medical	  students/residents	  
	   	   0.258	  
	  	  	  	  	  Yes	   137	   91.2	   	  
	  	  	  	  	  No	   180	   87.2	   	  
*	  Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data.	  









Table	  14.	  Unadjusted	  associations	  between	  practice	  characteristics	  and	  choice	  of	  Erlotinib	  as	  
first-­‐line	  regimen.	  	  
Characteristic	   N*	   %	  choosing	  Erlotinib	   p
†	  
Practice	  type	   	   	   0.013	  
	  	  	  	  	  Solo	  practice	   27	   70.4	   	  
	  	  	  	  	  Single	  specialty	  group	   130	   89.2	   	  
	  	  	  	  	  Multi-­‐specialty	  group	   123	   90.2	   	  
	  	  	  	  	  Other	   37	   97.3	   	  
%	  PTs	  with	  lung	  cancer,	  mean	  ±	  SD	   	   	   0.363	  
	  	  	  	  	  Erlotinib	   29.72	  ±	  27.88	   	   	  
	  	  	  	  	  Other	   25.24	  ±	  23.57	   	   	  
Paid	  by	  salary	  for	  clinical	  work	  in	  2011?	   	   	   0.877	  
	  	  	  	  	  Yes	   212	   89.2	   	  
	  	  	  	  	  No	   105	   88.6	   	  
Best	  describes	  personal	  clinical	  income†	   	   	   0.646	  
	  	  	  	  	  Exclusively	  fee-­‐for-­‐service	   50	   92.0	   	  
	  	  	  	  	  Predominantly	  fee-­‐for-­‐service	   37	   83.8	   	  
	  	  	  	  	  Equal	  mix	  of	  fee-­‐for-­‐service	  &	  capitation	   15	   86.7	   	  
	  	  	  	  	  Predominantly	  capitation	   2	   100.0	   	  
	  	  	  	  	  Exclusively	  capitation	   1	   100.0	   	  
Who	  owns	  the	  practice	   	   	   0.597	  
	  	  	  	  	  University	  or	  medical	  school	   38	   92.1	   	  
	  	  	  	  	  Federal,	  state,	  or	  local	  government	   14	   100.0	   	  
	  	  	  	  	  1	  or	  1+	  physicians/physician-­‐owned	  corp.	   130	   85.5	   	  
	  	  	  	  	  A	  hospital	   53	   89.8	   	  
	  	  	  	  	  HMO,	  health	  plan,	  or	  insurance	  company	   38	   92.7	   	  
	  	  	  	  	  Some	  other	  type	  of	  owner	   12	   92.3	   	  
	  	  	  	  	  Don’t	  know	   0	   0.0	   	  
How,	  if	  at	  all,	  income	  is	  mostly	  likely	  to	  change	  
as	  a	  result	  of	  prescribing/administering	  more	  
chemotherapy	  
	   	   0.289	  
	  	  	  	  	  Likely	  to	  decrease	   30	   80.0	   	  
	  	  	  	  	  Not	  likely	  to	  change	   213	   88.7	   	  
	  	  	  	  	  Likely	  to	  decrease	  	   57	   93.0	   	  
	  	  	  	  	  Don’t	  know	   17	   94.1	   	  
How,	  if	  at	  all,	  income	  is	  mostly	  likely	  to	  change	  
as	  a	  result	  of	  ordering	  more	  genetic	  testing	  
	   	   0.452	  
	  	  	  	  	  Likely	  to	  decrease	   8	   87.5	   	  
	  	  	  	  	  Not	  likely	  to	  change	   280	   88.6	   	  
	  	  	  	  	  Likely	  to	  increase	  	   16	   100.0	   	  
	  	  	  	  	  Don’t	  know	   13	   84.6	   	  
*	  Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data.	  
†	  P-­‐value	  for	  χ2	  test	  or	  Fisher’s	  Exact	  test,	  where	  appropriate.	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Table	  15.	  	  Unadjusted	  associations	  between	  impact	  of	  variables	  on	  requesting	  somatic	  genetic	  
testing	  and	  choice	  of	  Erlotinib	  as	  first-­‐line	  regimen.	  	  
Characteristic	   N*	   %	  choosing	  Erlotinib	   p
†	  
Whether	  or	  not	  local	  or	  national	  
guidelines	  have	  been	  issued	  on	  test	  
use	  
	  
	   0.066	  
	  	  	  	  	  Low	  impact	   18	   77.8	   	  
	  	  	  	  	  Moderate	  impact	   93	   85.0	   	  
	  	  	  	  	  High	  impact	   206	   91.8	   	  
FDA	  alerts	  about	  availability	  of	  test	   	   	   0.367	  
	  	  	  	  	  Low	  impact	   86	   90.7	   	  
	  	  	  	  	  Moderate	  impact	   145	   90.3	   	  
	  	  	  	  	  High	  impact	   86	   84.9	   	  
Test	  sensitivity	  and	  specificity	   	   	   0.822	  
	  	  	  	  	  Low	  impact	   13	   84.6	   	  
	  	  	  	  	  Moderate	  impact	   111	   88.3	   	  
	  	  	  	  	  High	  impact	   193	   89.6	   	  
Prevalence	  of	  genetic	  alteration	   	   	   0.185	  
	  	  	  	  	  Low	  impact	   44	   95.5	   	  
	  	  	  	  	  Moderate	  impact	   159	   86.2	   	  
	  	  	  	  	  High	  impact	   114	   90.4	   	  
Test	  predicts	  clinical	  benefit	  from	  
specific	  treatments	  
	   	   0.245	  
	  	  	  	  	  Low	  impact	   1	   100.0	   	  
	  	  	  	  	  Moderate	  impact	   30	   80.0	   	  
	  	  	  	  	  High	  impact	   286	   89.9	   	  
Test	  predicts	  toxicity	  from	  specific	  
treatments	  
	   	   0.297	  
	  	  	  	  	  Low	  impact	   22	   90.9	   	  
	  	  	  	  	  Moderate	  impact	   135	   91.9	   	  
	  	  	  	  	  High	  impact	   160	   86.3	   	  
Test	  predicts	  prognostic	  
information	  
	   	   0.818	  
	  	  	  	  	  Low	  impact	   20	   85.0	   	  
	  	  	  	  	  Moderate	  impact	   133	   88.7	   	  
	  	  	  	  	  High	  impact	   164	   89.6	   	  
Patient	  requests/inquires	  about	  
test	  
	   	   0.673	  
	  	  	  	  	  Low	  impact	   90	   86.7	   	  
	  	  	  	  	  Moderate	  impact	   181	   89.5	   	  
	  	  	  	  	  High	  impact	   46	   91.3	   	  
*	  Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data.	  
†	  P-­‐value	  for	  χ2	  test	  or	  Fisher’s	  Exact	  test,	  where	  appropriate.	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Table	  16.	  	  Unadjusted	  associations	  between	  how	  often	  physicians	  obtain	  information	  from	  the	  
following	  sources	  in	  order	  to	  learn	  about	  using	  a	  new	  somatic	  genetic	  test	  and	  choice	  of	  
Erlotinib	  as	  first-­‐line	  regimen.	  	  
Characteristic	   N*	   %	  choosing	  Erlotinib	   p
†	  
Local	  colleagues	   	   	   0.062	  
	  	  	  	  	  Never	   26	   73.1	   	  
	  	  	  	  	  Rarely	   90	   91.1	   	  
	  	  	  	  	  Sometimes	   149	   89.9	   	  
	  	  	  	  	  Often	   52	   90.4	   	  
National/international	  experts	   	   	   0.037	  
	  	  	  	  	  Never	   9	   55.6	   	  
	  	  	  	  	  Rarely	   36	   88.9	   	  
	  	  	  	  	  Sometimes	   127	   89.0	   	  
	  	  	  	  	  Often	   145	   91.0	   	  
Test	  manufacturer	  or	  drug	  
company	  representative	  
	   	   0.237	  
	  	  	  	  	  Never	   44	   93.2	   	  
	  	  	  	  	  Rarely	   118	   91.5	   	  
	  	  	  	  	  Sometimes	   125	   87.2	   	  
	  	  	  	  	  Often	   30	   80.0	   	  
National	  guidelines	   	   	   0.041	  
	  	  	  	  	  Never	   4	   50.0	   	  
	  	  	  	  	  Rarely	   8	   100.0	   	  
	  	  	  	  	  Sometimes	   	  69	   84.1	   	  
	  	  	  	  	  Often	   236	   90.7	   	  
Scientific	  meetings	  and	  
conferences	  
	   	   0.346	  
	  	  	  	  	  Never	   1	   100.0	   	  
	  	  	  	  	  Rarely	   20	   95.0	   	  
	  	  	  	  	  Sometimes	   114	   85.1	   	  
	  	  	  	  	  Often	   182	   90.7	   	  
Peer-­‐reviewed	  medical	  literature	   	   	   0.116	  
	  	  	  	  	  Never	   4	   50.0	   	  
	  	  	  	  	  Rarely	   12	   91.7	   	  
	  	  	  	  	  Sometimes	   94	   87.2	   	  
	  	  	  	  	  Often	   207	   90.3	   	  
Foundation	  or	  government	  website	   	   	   0.086	  
	  	  	  	  	  Never	   17	   70.6	   	  
	  	  	  	  	  Rarely	   80	   88.8	   	  
	  	  	  	  	  Sometimes	   127	   91.3	   	  
	  	  	  	  	  Often	   93	   89.3	   	  
Evidence-­‐based,	  synthesized	  
websites	  
	   	   0.425	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  Never	   23	   87.0	   	  
	  	  	  	  	  Rarely	   49	   83.7	   	  
	  	  	  	  	  Sometimes	   99	   87.9	   	  
	  	  	  	  	  Often	   146	   91.8	   	  
Test	  manufacturer	  or	  drug	  
company	  websites	  
	   	   0.026	  
	  	  	  	  	  Never	   104	   87.5	   	  
	  	  	  	  	  Rarely	   138	   94.2	   	  
	  	  	  	  	  Sometimes	   68	   82.4	   	  
	  	  	  	  	  Often	   7	   71.4	   	  
FDA	  package	  insert	   	   	   0.351	  
	  	  	  	  	  Never	   88	   88.6	   	  
	  	  	  	  	  Rarely	   121	   92.6	   	  
	  	  	  	  	  Sometimes	   92	   84.8	   	  
	  	  	  	  	  Often	   16	   87.5	   	  
*	  Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data.	  

























Table	  17.	  Final	  logistic	  regression	  model	  predicting	  choice	  of	  Erlotinib	  as	  first-­‐line	  regimen.	  
Variable	   OR	  (95%	  CI)	   p	  
Male	  	   	   2.75	  (1.07,	  7.05)	   0.035	  
Age	  	   0.93	  (0.89,	  0.98)	   0.005	  
Race	   	   0.031	  
	  	  	  	  	  	  Non-­‐Hispanic	  White	   1.00	   -­‐-­‐	  
	  	  	  	  	  	  	  Asian	   1.52	  (0.47,	  4.88)	   0.483	  
	  	  	  	  	  	  	  Other*	   0.27	  (0.09,	  0.77)	   0.014	  
	  	  	  	  	  	  	  Unknown†	   -­‐-­‐	   0.987	  
Graduation	  from	  U.S./Canadian	  medical	  school	   2.36	  (0.89,	  6.26)	   0.088	  
Practice	  type	   	   0.149	  
	  	  	  	  	  	  	  Solo	  practice	   1.00	   -­‐-­‐	  
	  	  	  	  	  	  	  Single	  specialty	  group	   1.71	  (0.52,	  5.67)	   0.378	  
	  	  	  	  	  	  	  Multi-­‐specialty	  group	   1.88	  (0.53,	  6.66)	   0.327	  
	  	  	  	  	  	  	  Other	   15.87	  (1.51,	  167.19)	   0.021	  
Impact	  on	  requesting	  somatic	  genetic	  testing	   	   	  
	  	  	  	  	  	  Whether	  or	  not	  local	  or	  national	  guidelines	  	  
	  	  	  	  	  	  	  have	  been	  issued	  on	  test	  	  
2.07	  (1.12,	  3.81)	   0.020	  
How	  often	  physicians	  obtain	  information	  from	  sources	  in	  
order	  to	  learn	  about	  using	  a	  new	  somatic	  genetic	  test	  
	   	  
	  	  	  	  	  	  	  National/international	  experts	   1.56	  (0.96,	  2.52)	   0.073	  
*	  Other	  includes	  non-­‐Hispanic	  Black,	  Native	  Hawaiian,	  other	  race,	  and	  multiracial.	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